Systematic Review of Tumor Necrosis Factor Antagonists in Extraintestinal Manifestations in Inflammatory Bowel Disease

BACKGROUND & AIMS: This systematic review investigated the efficacy and the effectiveness of biologic drugs in extraintestinal manifestations (EIMs) in inflammatory bowel disease (IBD). METHODS: Literature search was conducted in PubMed, Embase, and Cochrane until October 2015. Main inclusion cr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical Gastroenterology and Hepatology 2017, Vol.15 (1), p.25
Hauptverfasser: Peyrin-Biroulet, Laurent, Van Assche, Gert, Gomez-Ulloa, David, Garcia-Alvarez, Laura, Lara, Nuria, Black, Chris M, Kachroo, Sumesh
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 1
container_start_page 25
container_title Clinical Gastroenterology and Hepatology
container_volume 15
creator Peyrin-Biroulet, Laurent
Van Assche, Gert
Gomez-Ulloa, David
Garcia-Alvarez, Laura
Lara, Nuria
Black, Chris M
Kachroo, Sumesh
description BACKGROUND & AIMS: This systematic review investigated the efficacy and the effectiveness of biologic drugs in extraintestinal manifestations (EIMs) in inflammatory bowel disease (IBD). METHODS: Literature search was conducted in PubMed, Embase, and Cochrane until October 2015. Main inclusion criteria were adults with IBD, use of a biologic drug, evolution of EIMs, interventional study, or non-interventional study. RESULTS: Nine interventional studies (2 randomized controlled trials [N = 797], 7 open label trials [N = 1143], and 13 non-interventional studies [N = 914]) were included. Tumor necrosis factor (TNF) antagonists achieved complete response for pyoderma gangrenosum in 21%-25% of patients in interventional studies and in 92%-100% patients in non-interventional studies, with similar results for other cutaneous manifestations such as erythema nodosum or stomatitis. Adalimumab significantly reduced the prevalence of anemia vs placebo after 56 weeks in 1 randomized controlled trial. In 2 non-interventional studies, anti-TNF therapy improved anemia in the short-term (67%) and in the long-term (34%). Complete response after anti-TNF treatment was reported in interventional studies, including arthralgia (reduction in prevalence from 47.1% to 26.8% in the mid-term in 1 open label trial) and arthritis (reduction in prevalence from 8.7% to 2.1% and from 58% to 12.5% in 2 open label trials). Anti-TNFs were beneficial for a majority of patients with ocular manifestations. Infliximab was associated with improved outcomes in bone formation and bone mineral density. CONCLUSIONS: Anti-TNFs appear to be effective alternatives for certain EIMs associated with IBD including musculoskeletal, cutaneous, and ocular manifestations, and some beneficial effect may be obtained in metabolic bone disease and on hematologic or vascular EIMs.
format Article
fullrecord <record><control><sourceid>kuleuven</sourceid><recordid>TN_cdi_kuleuven_dspace_123456789_610793</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>123456789_610793</sourcerecordid><originalsourceid>FETCH-kuleuven_dspace_123456789_6107933</originalsourceid><addsrcrecordid>eNqNjLtOw0AQAK8AiRD4h-0oUCTb5wcueSSCIhSQ3lqZNVo47yHv2kn-HgvxAalGI43mzC3SIs9WviiLC3ep-pUkWZ3X1cJN70c16tG4hTeamPYQO9iNfRzgldohKitssLXZ78XwMwqrKbDA-mADshipsWCALQp3s8yvKH_Fi3QB-3kehyM8xD0FeGIlVLpy5x0Gpet_Lt3NZr17fF59j4HGiaT50B9sqUkznxdldVc3ZZpUtfdLd3ta2djB_OnfX3p0XAM</addsrcrecordid><sourcetype>Institutional Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Systematic Review of Tumor Necrosis Factor Antagonists in Extraintestinal Manifestations in Inflammatory Bowel Disease</title><source>Lirias (KU Leuven Association)</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Peyrin-Biroulet, Laurent ; Van Assche, Gert ; Gomez-Ulloa, David ; Garcia-Alvarez, Laura ; Lara, Nuria ; Black, Chris M ; Kachroo, Sumesh</creator><creatorcontrib>Peyrin-Biroulet, Laurent ; Van Assche, Gert ; Gomez-Ulloa, David ; Garcia-Alvarez, Laura ; Lara, Nuria ; Black, Chris M ; Kachroo, Sumesh</creatorcontrib><description>BACKGROUND &amp; AIMS: This systematic review investigated the efficacy and the effectiveness of biologic drugs in extraintestinal manifestations (EIMs) in inflammatory bowel disease (IBD). METHODS: Literature search was conducted in PubMed, Embase, and Cochrane until October 2015. Main inclusion criteria were adults with IBD, use of a biologic drug, evolution of EIMs, interventional study, or non-interventional study. RESULTS: Nine interventional studies (2 randomized controlled trials [N = 797], 7 open label trials [N = 1143], and 13 non-interventional studies [N = 914]) were included. Tumor necrosis factor (TNF) antagonists achieved complete response for pyoderma gangrenosum in 21%-25% of patients in interventional studies and in 92%-100% patients in non-interventional studies, with similar results for other cutaneous manifestations such as erythema nodosum or stomatitis. Adalimumab significantly reduced the prevalence of anemia vs placebo after 56 weeks in 1 randomized controlled trial. In 2 non-interventional studies, anti-TNF therapy improved anemia in the short-term (67%) and in the long-term (34%). Complete response after anti-TNF treatment was reported in interventional studies, including arthralgia (reduction in prevalence from 47.1% to 26.8% in the mid-term in 1 open label trial) and arthritis (reduction in prevalence from 8.7% to 2.1% and from 58% to 12.5% in 2 open label trials). Anti-TNFs were beneficial for a majority of patients with ocular manifestations. Infliximab was associated with improved outcomes in bone formation and bone mineral density. CONCLUSIONS: Anti-TNFs appear to be effective alternatives for certain EIMs associated with IBD including musculoskeletal, cutaneous, and ocular manifestations, and some beneficial effect may be obtained in metabolic bone disease and on hematologic or vascular EIMs.</description><identifier>ISSN: 1542-3565</identifier><language>eng</language><publisher>NEW YORK: W.B. Saunders for the American Gastroenterological Association</publisher><ispartof>Clinical Gastroenterology and Hepatology, 2017, Vol.15 (1), p.25</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,315,776,780,4010,27837</link.rule.ids></links><search><creatorcontrib>Peyrin-Biroulet, Laurent</creatorcontrib><creatorcontrib>Van Assche, Gert</creatorcontrib><creatorcontrib>Gomez-Ulloa, David</creatorcontrib><creatorcontrib>Garcia-Alvarez, Laura</creatorcontrib><creatorcontrib>Lara, Nuria</creatorcontrib><creatorcontrib>Black, Chris M</creatorcontrib><creatorcontrib>Kachroo, Sumesh</creatorcontrib><title>Systematic Review of Tumor Necrosis Factor Antagonists in Extraintestinal Manifestations in Inflammatory Bowel Disease</title><title>Clinical Gastroenterology and Hepatology</title><description>BACKGROUND &amp; AIMS: This systematic review investigated the efficacy and the effectiveness of biologic drugs in extraintestinal manifestations (EIMs) in inflammatory bowel disease (IBD). METHODS: Literature search was conducted in PubMed, Embase, and Cochrane until October 2015. Main inclusion criteria were adults with IBD, use of a biologic drug, evolution of EIMs, interventional study, or non-interventional study. RESULTS: Nine interventional studies (2 randomized controlled trials [N = 797], 7 open label trials [N = 1143], and 13 non-interventional studies [N = 914]) were included. Tumor necrosis factor (TNF) antagonists achieved complete response for pyoderma gangrenosum in 21%-25% of patients in interventional studies and in 92%-100% patients in non-interventional studies, with similar results for other cutaneous manifestations such as erythema nodosum or stomatitis. Adalimumab significantly reduced the prevalence of anemia vs placebo after 56 weeks in 1 randomized controlled trial. In 2 non-interventional studies, anti-TNF therapy improved anemia in the short-term (67%) and in the long-term (34%). Complete response after anti-TNF treatment was reported in interventional studies, including arthralgia (reduction in prevalence from 47.1% to 26.8% in the mid-term in 1 open label trial) and arthritis (reduction in prevalence from 8.7% to 2.1% and from 58% to 12.5% in 2 open label trials). Anti-TNFs were beneficial for a majority of patients with ocular manifestations. Infliximab was associated with improved outcomes in bone formation and bone mineral density. CONCLUSIONS: Anti-TNFs appear to be effective alternatives for certain EIMs associated with IBD including musculoskeletal, cutaneous, and ocular manifestations, and some beneficial effect may be obtained in metabolic bone disease and on hematologic or vascular EIMs.</description><issn>1542-3565</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>FZOIL</sourceid><recordid>eNqNjLtOw0AQAK8AiRD4h-0oUCTb5wcueSSCIhSQ3lqZNVo47yHv2kn-HgvxAalGI43mzC3SIs9WviiLC3ep-pUkWZ3X1cJN70c16tG4hTeamPYQO9iNfRzgldohKitssLXZ78XwMwqrKbDA-mADshipsWCALQp3s8yvKH_Fi3QB-3kehyM8xD0FeGIlVLpy5x0Gpet_Lt3NZr17fF59j4HGiaT50B9sqUkznxdldVc3ZZpUtfdLd3ta2djB_OnfX3p0XAM</recordid><startdate>2017</startdate><enddate>2017</enddate><creator>Peyrin-Biroulet, Laurent</creator><creator>Van Assche, Gert</creator><creator>Gomez-Ulloa, David</creator><creator>Garcia-Alvarez, Laura</creator><creator>Lara, Nuria</creator><creator>Black, Chris M</creator><creator>Kachroo, Sumesh</creator><general>W.B. Saunders for the American Gastroenterological Association</general><scope>FZOIL</scope></search><sort><creationdate>2017</creationdate><title>Systematic Review of Tumor Necrosis Factor Antagonists in Extraintestinal Manifestations in Inflammatory Bowel Disease</title><author>Peyrin-Biroulet, Laurent ; Van Assche, Gert ; Gomez-Ulloa, David ; Garcia-Alvarez, Laura ; Lara, Nuria ; Black, Chris M ; Kachroo, Sumesh</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-kuleuven_dspace_123456789_6107933</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Peyrin-Biroulet, Laurent</creatorcontrib><creatorcontrib>Van Assche, Gert</creatorcontrib><creatorcontrib>Gomez-Ulloa, David</creatorcontrib><creatorcontrib>Garcia-Alvarez, Laura</creatorcontrib><creatorcontrib>Lara, Nuria</creatorcontrib><creatorcontrib>Black, Chris M</creatorcontrib><creatorcontrib>Kachroo, Sumesh</creatorcontrib><collection>Lirias (KU Leuven Association)</collection><jtitle>Clinical Gastroenterology and Hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Peyrin-Biroulet, Laurent</au><au>Van Assche, Gert</au><au>Gomez-Ulloa, David</au><au>Garcia-Alvarez, Laura</au><au>Lara, Nuria</au><au>Black, Chris M</au><au>Kachroo, Sumesh</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Systematic Review of Tumor Necrosis Factor Antagonists in Extraintestinal Manifestations in Inflammatory Bowel Disease</atitle><jtitle>Clinical Gastroenterology and Hepatology</jtitle><date>2017</date><risdate>2017</risdate><volume>15</volume><issue>1</issue><spage>25</spage><pages>25-</pages><issn>1542-3565</issn><abstract>BACKGROUND &amp; AIMS: This systematic review investigated the efficacy and the effectiveness of biologic drugs in extraintestinal manifestations (EIMs) in inflammatory bowel disease (IBD). METHODS: Literature search was conducted in PubMed, Embase, and Cochrane until October 2015. Main inclusion criteria were adults with IBD, use of a biologic drug, evolution of EIMs, interventional study, or non-interventional study. RESULTS: Nine interventional studies (2 randomized controlled trials [N = 797], 7 open label trials [N = 1143], and 13 non-interventional studies [N = 914]) were included. Tumor necrosis factor (TNF) antagonists achieved complete response for pyoderma gangrenosum in 21%-25% of patients in interventional studies and in 92%-100% patients in non-interventional studies, with similar results for other cutaneous manifestations such as erythema nodosum or stomatitis. Adalimumab significantly reduced the prevalence of anemia vs placebo after 56 weeks in 1 randomized controlled trial. In 2 non-interventional studies, anti-TNF therapy improved anemia in the short-term (67%) and in the long-term (34%). Complete response after anti-TNF treatment was reported in interventional studies, including arthralgia (reduction in prevalence from 47.1% to 26.8% in the mid-term in 1 open label trial) and arthritis (reduction in prevalence from 8.7% to 2.1% and from 58% to 12.5% in 2 open label trials). Anti-TNFs were beneficial for a majority of patients with ocular manifestations. Infliximab was associated with improved outcomes in bone formation and bone mineral density. CONCLUSIONS: Anti-TNFs appear to be effective alternatives for certain EIMs associated with IBD including musculoskeletal, cutaneous, and ocular manifestations, and some beneficial effect may be obtained in metabolic bone disease and on hematologic or vascular EIMs.</abstract><cop>NEW YORK</cop><pub>W.B. Saunders for the American Gastroenterological Association</pub></addata></record>
fulltext fulltext
identifier ISSN: 1542-3565
ispartof Clinical Gastroenterology and Hepatology, 2017, Vol.15 (1), p.25
issn 1542-3565
language eng
recordid cdi_kuleuven_dspace_123456789_610793
source Lirias (KU Leuven Association); Elsevier ScienceDirect Journals Complete
title Systematic Review of Tumor Necrosis Factor Antagonists in Extraintestinal Manifestations in Inflammatory Bowel Disease
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T07%3A23%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-kuleuven&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Systematic%20Review%20of%20Tumor%20Necrosis%20Factor%20Antagonists%20in%20Extraintestinal%20Manifestations%20in%20Inflammatory%20Bowel%20Disease&rft.jtitle=Clinical%20Gastroenterology%20and%20Hepatology&rft.au=Peyrin-Biroulet,%20Laurent&rft.date=2017&rft.volume=15&rft.issue=1&rft.spage=25&rft.pages=25-&rft.issn=1542-3565&rft_id=info:doi/&rft_dat=%3Ckuleuven%3E123456789_610793%3C/kuleuven%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true